Answers are grounded in this paper and cite their sources.
Introduction Epithelial ovarian cancer (EOC) has a high recurrence rate and lacks reliable noninvasive prognostic biomarkers. Our previous work showed that plasma exosomal miR-4479 and miR-6763-5p have diagnostic value, but their prognostic role is unclear. This study aimed to evaluate their associations with postoperative progression-free survival (PFS) and assess the incremental prognostic value of miR-6763-5p in EOC. Methods This single-center prospective study included 126 newly diagnosed EOC patients. Associations with PFS were analyzed using Kaplan–Meier and Cox regression. Incremental value was assessed by nested model comparisons, with internal validation using 1,000 bootstrap resamples. Results During follow-up, 72 PFS events occurred. Low miR-6763-5p expression was significantly associated with poorer PFS (HR = 0.500, P = 0.004). Adding miR-6763-5p to the clinical model significantly improved model fit (likelihood ratio test: χ² = 8.319, P = 0.004), indicating additional prognostic information beyond conventional clinicopathological factors. Discussion Pretreatment plasma exosomal miR-6763-5p provides incremental prognostic information for postoperative PFS in EOC, but external validation is required before clinical use.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: